Skip to content

Trial Summary

This is a Phase 2/3, randomized study in subjects with progressive desmoid tumors consisting of 2 parts. Part A is an open-label, dose regimen finding study; Part B is a double blind, placebo-controlled study utilizing the dose regimen selected in Part A.



ACTRN/NCT /ethics:


Scientific title:

A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients With Progressing Desmoid Tumors

Sponsor / Cooperative group:

Ayala Pharmaceuticals, Inc

Trial & Patient Characteristics

Cancer TypeOther
Trial TypeTreatment
PhasePhase II, Phase III
Age Range18 years and older
Tumour Stream -
Cancer StageAll stages
Anticipated Start Date2021-03-30
Anticipated End Date2025-01-12

Participating Hospitals

HospitalIcon Cancer Centre - Tennyson and Windsor Garden
Clinical Trial CoordinatorSue Yeend
Phone08 8292 2204
Principal InvestigatorNimit Singhal
Recruitment StatusRecruiting